ADMA Biologics, Inc. (ADMA)
9.385
+0.04
(+0.48%)
USD |
NASDAQ |
Aug 31, 16:00
9.385
0.00 (0.00%)
After-Hours: 20:00
ADMA Biologics Cash from Operations (TTM) : 136.72M for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 136.72M |
| March 31, 2026 | 128.32M |
| December 31, 2025 | 50.40M |
| September 30, 2025 | 64.97M |
| June 30, 2025 | 76.71M |
| March 31, 2025 | 101.22M |
| December 31, 2024 | 118.67M |
| September 30, 2024 | 86.05M |
| June 30, 2024 | 73.01M |
| March 31, 2024 | 21.30M |
| December 31, 2023 | 8.80M |
| September 30, 2023 | -16.18M |
| June 30, 2023 | -41.45M |
| March 31, 2023 | -48.22M |
| December 31, 2022 | -59.51M |
| September 30, 2022 | -85.59M |
| June 30, 2022 | -85.72M |
| March 31, 2022 | -105.15M |
| December 31, 2021 | -112.37M |
| September 30, 2021 | -111.12M |
| June 30, 2021 | -121.56M |
| March 31, 2021 | -110.59M |
| December 31, 2020 | -102.00M |
| September 30, 2020 | -89.44M |
| June 30, 2020 | -89.21M |
| Date | Value |
|---|---|
| March 31, 2020 | -86.55M |
| December 31, 2019 | -76.19M |
| September 30, 2019 | -75.33M |
| June 30, 2019 | -64.25M |
| March 31, 2019 | -60.53M |
| December 31, 2018 | -62.68M |
| September 30, 2018 | -57.24M |
| June 30, 2018 | -54.44M |
| March 31, 2018 | -48.31M |
| December 31, 2017 | -37.27M |
| September 30, 2017 | -27.53M |
| June 30, 2017 | -22.47M |
| March 31, 2017 | -18.50M |
| December 31, 2016 | -18.27M |
| September 30, 2016 | -18.73M |
| June 30, 2016 | -16.72M |
| March 31, 2016 | -16.37M |
| December 31, 2015 | -15.42M |
| September 30, 2015 | -14.24M |
| June 30, 2015 | -14.04M |
| March 31, 2015 | -13.89M |
| December 31, 2014 | -14.70M |
| September 30, 2014 | -14.76M |
| June 30, 2014 | -14.52M |
| March 31, 2014 | -12.85M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Erasca, Inc. | -98.02M |
| Krystal Biotech, Inc. | 272.34M |
| Vericel Corp. | 69.67M |
| Emergent BioSolutions, Inc. | 97.70M |
| Exelixis, Inc. | 1.183B |